NCT04334330: Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

NCT04334330
Breast Cancer Type: HER2+
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: 

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have tumors that express both HER2 & ER; Patients must have at least 1 new brain lesion (greater than or equal to 10 mm)
Exclusions: Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04334330

Comments are closed.

Up ↑